Shire ADHD treatment Intuniv gets EU approval
pharmafile | September 21, 2015 | News story | Sales and Marketing | ADHD, Shire, attention deficit hyperactivity disorder, intuniv
The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children.
Intuniv (guanfacine hydrochloride prolonged release tablets) is a once-daily, extended-release, non-stimulant. It is the first drug of its kind – a selective alpha-2A adrenergic receptor agonist – to be licensed for the treatment of ADHD in the EU.
ADHD is a WHO-recognised common psychiatric disorder in children and adolescents, the common symptoms of which are inattention, hyperactivity and impulsivity. Worldwide prevalence of the condition is estimated to be between about 5 and 7%, and just under 5% for children and adolescents. The disorder is believed to be caused by a combination of genetic and environmental factors.
Perry Sternberg, senior vice president of the neuroscience business unit at Shire, comments: “The approval of Intuniv marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these patients.
“The importance of simply providing physicians with the ability to choose the non-stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents.”
The European Commission’s decision to grant approval is based on data from three pivotal Phase III studies investigating the short and long-term safety and efficacy of Intuniv in children and adolescents with ADHD.
Intuniv had previously received approval in the US and Canada. However Shire’s American sales of the drug are currently under threat as a result of generic competition from Sandoz, which introduced its own version to the market in June of this year.
Actavis also launched a generic version in December 2014, after reaching a settlement with Shire whereby the Irish drugmaker received 25% of profits during Actavis’s six-month period of market exclusivity.
Joel Levy
Related Content
Proof-of-concept study shows non-invasive brain stimulation efficient as treatment for ADHD in children
Researchers from the University of Surrey, UK, and the Hebrew University of Jerusalem, Israel, have …
PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial
Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine …
Expansion for first FDA-approved video game for ADHD treatment
Akili Interactive has announced the expansion of its prescription video game treatment, EndeavorRx, with the …